U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Curis, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose ...

Related Keywords

,Curis Inc ,Drug Administration ,Takeaim Leukemia Phase ,Acute Myelogenous Leukemia ,Myelodysplastic Syndromes ,Takeaim Leukemia ,Complete Response ,Partial Hematologic Recovery ,